Citations

Showing 10 of 108152 citations.

Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Quinn, Michael C. , McCue, Karen, Shi, Wei , Johnatty, Sharon E. , Beesley, Jonathan, Civitarese, Andrew, O’Mara, Tracy A. , Glubb, Dylan M. , Armasu, Sebastian M. , Ong, Jue‐Sheng , Lu, Yi , Gao, Bo , Patch, Ann‐Marie , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, García, María J. , Goodman, Marc T. , Dörk, Thilo , Moysich, Kirsten B. , Pfisterer, Jacobus , Bauman, Klaus, Lester, Jenny , Cunningham, Julie M. , McCauley, Bryan M. , Høgdall, Claus , Schildkraut, Joellen M. , Riggan, Marjorie J. , Terry, Kathryn L. , Webb, Penelope M. , May, Taymaa, Ene, Gabrielle, Huntsman, David G., Woo, Michelle, Carney, Michael E. , Fereday, Sián , Kennedy, Catherine J. , Edwards, Stacey L. , DeFazio, Anna , Goode, Ellen L. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Lambrechts, Diether , Quinn, Michael C J , Ong, Jue-Sheng , Gharahkhani, Puya , Lu, Yi , Fasching, Peter A , Lambrechts, Diether , Vergote, Ignace , Dörk, Thilo , Dürst, Matthias , Modugno, Francesmary , Bois, Andreas du , Karlan, Beth Y , Cunningham, Julie M , Kjaer, Susanne K , Webb, Penelope M , Friedlander, Michael , Glasspool, Rosalind , Hinsley, Samantha , Heitz, Florian , Kennedy, Catherine J , Winham, Stacey J , Fazio, Anna de , Pharoah, Paul D P , MacGregor, Stuart , Lambrechts, Diether , Moysich, Kirsten , O'Mara, Tracy A , Chenevix-Trench, Georgia , Høgdall, Claus K , Fereday, Sian , Goodman, Marc T , Beesley, Jonathan, Tyrer, Jonathan P. , Gharahkhani, Puya , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Modugno, Francesmary , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Jensen, Allan , Høgdall, Estrid , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Friedländer, Michael , Pejovic, Tanja B. , Moffitt, Melissa , Glasspool, Rosalind , Heitz, Florian , Winham, Stacey J. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 23, 2021 | Volume: 30 | Issue: 9 | Pages: 1669-1680

10.1158/1055-9965.epi-20-1817 | PMID 34162658 Get It

Abstract Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. Methods: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. Results: We found seven SNPs at 12q24.33 associated with PFS (P < 5 × 10–8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15–1.34; P = 1.47 × 10–8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. Conclusions: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. Impact: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options. See related commentary by Peres and Monteiro, p. 1604
Ciliopathy protein HYLS1 coordinates the biogenesis and signaling of primary cilia by activating the ciliary lipid kinase PIPKIγ
Chen, Chuan , Xu, Qingwen , Davies, Brian A., Katzmann, David J. , Harris, Peter C. , Hu, Jinghua , Ling, Kun , Zhang, Yuxia , Hu, Jinghua , Ling, Kun , Harris, Peter C , Chen, Chuan , Huang, Yan

Mayo Clinic

Science Advances | June 23, 2021 | Volume: 7 | Issue: 26 | Pages: No page available

10.1126/sciadv.abe3401 | PMID 34162535 Get It

HYLS1 regulates the ciliary phosphoinositide and hedgehog pathways, implicating a novel pathogenic mechanism for HLS syndrome.
Mammographic Variation Measures, Breast Density, and Breast Cancer Risk
Heine, John , Fowler, Erin , Jensen, Matthew R. , Brandt, Kathleen R. , Wu, Fang , Miglioretti, Diana L. , Vachon, Celine M. , Wu, Fang F, Miglioretti, Diana L , Scott, Christopher G. , Shepherd, John , Hruska, Carrie B. , Winham, Stacey J. , Norman, Aaron D. , Pankratz, V. Shane , Kerlikowske, Karla , Vachon, Celine M.

Mayo Clinic

American Journal of Roentgenology | June 23, 2021 | Volume: 217 | Issue: 2 | Pages: 326-335

10.2214/ajr.20.22794 | PMID 34161135 Get It

Association of vitamin D deficiency with COVID‐19 infection severity: Systematic review and meta‐analysis
Joshi, Avni Y. , Leopold, Kaitlin , Christensen, Stephanie , Nayfeh, Tarek , Mohammed, Khaled , Creo, Ana L. , Tebben, Peter J. , Kumar, Seema , Joshi, Avni, Jackson, Sarah, Creo, Ana , Tebben, Peter, Kumar, Seema , Nayfeh, Tarek , Tebben, Peter , Wang, Zhen , Jackson, Sarah

Mayo Clinic

Clinical Endocrinology | June 23, 2021 | Volume: 96 | Issue: 3 | Pages: 281-287

10.1111/cen.14540 | PMID 34160843 Get It

AbstractBackgroundWe sought to evaluate the association between vitamin D deficiency and the severity of coronavirus disease 2019 (COVID‐19) infection.MethodsMultiple databases from 1 January 2019 to 3 December 2020 were searched for observational studies evaluating the association between vitamin D deficiency and severity of COVID‐19 infection. Independent reviewers selected studies and extracted data for the review. The main outcomes of interest were mortality, hospital admission, length of hospital stay and intensive care unit admission.ResultsSeventeen observational studies with 2756 patients were included in the analyses. Vitamin D deficiency was associated with significantly higher mortality (odds ratio [OR]: 2.47, 95% confidence interval [CI]: 1.50–4.05; 12 studies; hazard ratio [HR]: 4.11, 95% CI: 2.40–7.04; 3 studies), higher rates of hospital admissions (OR: 2.18, 95% CI: 1.48–3.21; 3 studies) and longer hospital stays (0.52 days; 95% CI: 0.25–0.80; 2 studies) as compared to nonvitamin D deficient status. Subgroup analyses based on different cut‐offs for defining vitamin D deficiency, study geographic locations and latitude also showed similar trends.ConclusionsVitamin D deficiency is associated with greater severity of COVID‐19 infection. Further studies are warranted to determine if vitamin D supplementation can decrease the severity of COVID‐19.
Reflections of an Outgoing Editor-in-Chief
Sieck, Gary C.

Mayo Clinic

Physiology | June 23, 2021 | Volume: 36 | Issue: 4 | Pages: 196-196

10.1152/physiol.00018.2021 | PMID 34159802 Get It

Physiology in Perspective: Eat, Sleep, Survive—Natural Cycle of Life
Sieck, Gary C.

Mayo Clinic

Physiology | June 23, 2021 | Volume: 36 | Issue: 4 | Pages: 201-202

10.1152/physiol.00017.2021 | PMID 34159806 Get It

A Century of Insulin: Outstanding Physiological Breakthroughs
Matveyenko, Aleksey V. , Klip, Amira , Matveyenko, Aleksey, Sieck, Gary C.

Mayo Clinic

Physiology | June 23, 2021 | Volume: 36 | Issue: 4 | Pages: 197-200

10.1152/physiol.00016.2021 | PMID 34159804 Get It

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
Li, Juanni , Huang, Jinzhou , Xu, Zhijie , Xu, Zhijie , Hu, Kuan , Zhou, Lei , Yan, Yuanliang

Mayo Clinic

Aging | June 23, 2021 | Volume: 13 | Issue: 12 | Pages: 16541-16566

10.18632/aging.203175 | PMID 34160364 Get It

Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review‐based cohort study
Dymanus, Kyle , Butaney, Mohit , Magee, Diana , Hird, Amanda , Luckenbaugh, Amy N. , Merry, W. , Hall, Mary E. , Laviana, Aaron A. , Davis, Nancy B. , Klaassen, Zachary , Dymanus, Kyle A , Magee, Diana E , Hird, Amanda E , Wallis, Christopher J D , Huelster, Heather L. , Terris, Martha K.

Mayo Clinic

Cancer | June 23, 2021 | Volume: 127 | Issue: 17 | Pages: 3156-3162

10.1002/cncr.33533 | PMID 34160824 Get It

Background Ensuring representative data accrual in clinical trials is important to safeguard the generalizability of results and to minimize disparities in care. This study's goal was to evaluate differences in gender representation in trials leading to US Food and Drug Administration (FDA) cancer drug approvals. Methods An observational study was conducted from January 2014 to April 2019 using PubMed and the National Institutes of Health trials registry for primary trial reports. The National Cancer Institute's Surveillance, Epidemiology, and End Results program and US Census were consulted for national cancer incidence. The outcome was an enrollment incidence disparity (EID), which was calculated as the difference between male and female trial enrollment and national incidence, with positive values representing male overrepresentation. Results There were 149 clinical trials with 59,988 participants—60.3% and 39.7% were male and female, respectively—leading to 127 oncology drug approvals. The US incidence rates were 55.4% for men versus 44.6% for women. Gender representation varied by specific tumor type. Most notably, women were underrepresented in thyroid cancer (EID, +27.4%), whereas men were underrepresented in soft tissue cancer (EID, –26.1%). Overall, women were underrepresented when compared with expected incidence (EID, +4.9%; 42% of trials). Conclusions For many specific tumor types, women are underrepresented in clinical trials leading to FDA oncology drug approvals. It is critical to better align clinical trial cohort demographics and the populations to which these data will be extrapolated. Lay Summary This study assesses whether gender disparities exist in clinical trials leading to US Food and Drug Administration (FDA) cancer drug approvals. From January 2014 to April 2019, 149 clinical trials leading to FDA oncology drug approvals showed 60.3% and 39.7% of the enrollees were male and female, respectively. Gender representation varied by specific tumor when compared with the expected incidence rate of cancer in the United States, although women were more often underrepresented. Increased efforts are needed with regard to ensuring equitable representation in oncology clinical trials.
Epidemiology and trends in survival of systemic sclerosis in Olmsted County (1980–2018): A population-based study
Coffey, Caitrín M. , Radwan, Yasser , Sandhu, Avneek Singh, Crowson, Cynthia S. , Bauer, Philippe R. , Matteson, Eric L. , Makol, Ashima , Bauer, Philippe R , Makol, Ashima

Mayo Clinic

Journal of Scleroderma and Related Disorders | June 23, 2021 | Volume: 6 | Issue: 3 | Pages: 264-270

10.1177/23971983211026853 | PMID 35295789 Get It

Background/Purpose: To update the epidemiology of systemic sclerosis and evaluate the performance of the American College of Rheumatology/European League Against Rheumatism 2013 versus 1980 American Rheumatism Association classification criteria in a US population-based cohort. Methods: An inception cohort of patients with incident systemic sclerosis from 1 January 1980 through 31 December 2018, in Olmsted County, Minnesota, was identified based on comprehensive individual medical record review. Incidence and prevalence rates were age- and sex-adjusted to the 2010 US white population. Survival rates were compared with expected rates in the general population. Fulfillment of 1980 and 2013 classification criteria was ascertained. Results: A total of 85 incident cases of systemic sclerosis (91% female, mean age = 55.4 ± 16 years) and 49 prevalent cases on 1 January 2015 were identified. The overall age- and sex-adjusted annual incidence was 25 (95% confidence interval = 20–31) per million population, with no change in incidence over time. The age- and sex-adjusted prevalence was 436 (95% confidence interval = 313–558) per 1,000,000 population. 77 (91%) patients fulfilled the 2013 classification criteria, and 38 (45%) fulfilled the 1980 criteria. Mortality among patients with systemic sclerosis was significantly higher in comparison to the general population, with a standardized mortality ratio of 2.48 (95% confidence interval = 1.76–3.39) and no evidence of improvement over time. Conclusion: Systemic sclerosis developed in 25 persons/million/year with no change over the 39-year study period. The 2013 classification criteria perform significantly better than the 1980 criteria but failed to classify 9% of patients. Systemic sclerosis portends a 2.5-fold higher risk of mortality than the general population, with no evidence of improved survival over time.